Home › Funds › THOMAS STORY & SON LLC › ABT

THOMAS STORY & SON LLC position in ABT

ABBOTT LABORATORIES · Health Care

THOMAS STORY & SON LLC reported holding 73,989 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$7.3M, representing 2.52% of its reported portfolio and ranking #18 among its reported holdings. THOMAS STORY & SON LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)73.99K sh
Reported value held$7.31M
Portfolio Weight2.52%
First reportedQ3 2023
Last changeAdd
Updated2026-10-15

Last updated: 2026-10-15 · Source: SEC EDGAR Form 13F-HR

How THOMAS STORY & SON LLC's ABT position evolved

THOMAS STORY & SON LLC first disclosed a stake in ABT in Q3 2023 at 52,895 shares (US$5.1M). The position peaked in Q2 2025 at 67,479 shares, worth US$9.2M. Across 13 filings, THOMAS STORY & SON LLC increased the stake 5 time(s), trimmed it 3 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 73,989 shares valued at US$7.3M — an increase of 3,429 shares quarter over quarter.. Notable position changes include a 50% increase in Q3 2024 (shares were roughly flat over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 52.90K $5.12M New
Q4 2023 52.83K $5.81M Hold
Q1 2024 52.83K $6.00M Hold
Q2 2024 44.33K $4.61M Reduce
Q3 2024 66.54K $7.59M Add
Q4 2024 65.59K $7.42M Reduce
Q1 2025 67.59K $8.97M Add
Q2 2025 67.48K $9.18M Hold
Q3 2025 67.28K $9.01M Hold
Q4 2025 66.65K $8.35M Reduce
Q1 2026 69.73K $7.16M Add
Q2 2026 70.56K $6.40M Add
Q3 2026 73.99K $7.31M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has THOMAS STORY & SON LLC held ABT?

THOMAS STORY & SON LLC has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is THOMAS STORY & SON LLC's current position in ABT?

As of Q3 2026, THOMAS STORY & SON LLC holds 73.99K shares of ABT (ABBOTT LABORATORIES), valued at $7.31M, representing 2.52% of its reported portfolio and ranking #18.

Has THOMAS STORY & SON LLC been buying or selling ABT?

In the latest 13F filing (Q3 2026), THOMAS STORY & SON LLC increased its position in ABT. The position peaked in Q2 2025 at 67.48K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.